GlassScriptPhysician profile
Gregory Spana
NPI 1639314628
$4,589.28
in general payments reported to CMS, 2019-2025
46 companies · $684 in 2025
The $684 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $195 · 2021: $78.95 · 2022: $931 · 2023: $1,137 · 2024: $685 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $459.65 | 2019-2023 | Myrbetriq, Xtandi |
| Abbvie INC. | $394.88 | 2019-2025 | Botox, Lupron Depot |
| Sumitomo Pharma America, INC. | $348.34 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $268.50 | 2022-2025 | |
| Pfizer INC. | $240.52 | 2019-2025 | |
| Intuitive Surgical, INC. | $210.43 | 2022-2023 | Da Vinci Surgical System |
| Janssen Biotech, INC. | $183.02 | 2019-2025 | Erleada |
| Urovant Sciences INC | $163.05 | 2022 | |
| Merck Sharp & Dohme LLC | $159.14 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Coloplast Corp | $134.34 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $131.99 | 2022-2024 | Prolaris |
| Verity Pharmaceuticals INC. | $123.28 | 2022-2025 | Trelstar |
| Amgen INC. | $118.33 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $113.81 | 2024-2025 | |
| Neotract INC. | $106.64 | 2019 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Spana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.